6 results on '"triphenylphosphonium salts"'
Search Results
2. New Triphenylphosphonium Salts of Spiropyrans: Synthesis and Photochromic Properties.
- Author
-
Khuzin, Artur A., Galimov, Dim I., Khuzina, Liliya L., and Tukhbatullin, Adis A.
- Subjects
- *
DIARYLETHENE , *SPIROPYRANS , *DOSAGE forms of drugs , *SALTS - Abstract
The most important area of modern pharmacology is the targeted delivery of drugs, and one of the most promising classes of chemical compounds for creating drugs of this kind are the photochromic spiropyrans, capable of light-controlled biological activity. This work is devoted to the synthesis and study of the photochromic properties of new triphenylphosphonium salts of spiropyrans. It was found that all the synthesized cationic spiropyrans have high photosensitivity, increased resistance to photodegradation and the ability for photoluminescence. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Oncogenic and telomeric G-quadruplexes: Targets for porphyrin-triphenylphosphonium conjugates.
- Author
-
Moura, Nuno M.M., Guedes, Sofia, Salvador, Diana, Oliveira, Helena, Alves, Mariana Q., Paradis, Nicholas, Wu, Chun, Neves, M. Graça P.M.S., and Ramos, Catarina I.V.
- Subjects
- *
LIGANDS (Biochemistry) , *MOLECULAR dynamics , *QUADRUPLEX nucleic acids , *NON-coding RNA , *REACTIVE oxygen species - Abstract
DNA chains with sequential guanine (G) repeats can lead to the formation of G-quadruplexes (G4), which are found in functional DNA and RNA regions like telomeres and oncogene promoters. The development of molecules with adequate structural features to selectively stabilize G4 structures can counteract cell immortality, highly described for cancer cells, and also downregulate transcription events underlying cell apoptosis and/or senescence processes. We describe here, the efficiency of four highly charged porphyrins-phosphonium conjugates to act as G4 stabilizing agents. The spectrophotometric results allowed to select the conjugates P2-PPh 3 and P3-PPh 3 as the most promising ones to stabilize selectively G4 structures. Molecular dynamics simulation experiments were performed and support the preferential binding of P2-PPh 3 namely to MYC and of P3-PPh 3 to KRAS. The ability of both ligands to block the activity of Taq polymerase was confirmed and also their higher cytotoxicity against the two melanoma cell lines A375 and SK-MEL-28 than to immortalized skin keratinocytes. Both ligands present efficient cellular uptake, nuclear co-localization and high ability to generate 1O 2 namely when interacting with G4 structure. The obtained data points the synthesized porphyrins as promising ligands to be used in a dual approach that can combine G4 stabilization and Photodynamic therapy (PDT). • New porphyrin-triphenylphosphonium (Px-PPh 3) conjugates, owing 4 to 8+ positive charges, were synthesized • P2-PPh 3 and P3-PPh 3 conjugates showed high affinity and selectivity for G-quadruplexes (G4) and end-stacking binding mode on the top of G4 • PCR stop assays revealed the ability of P2-PPh 3 and P3-PPh 3 conjugates to block Taq polymerase activity • P2-PPh 3 and P3-PPh 3 showed greater cytotoxic effect, efficient cellular uptake in melanoma cells and nuclear co-localization • P2-PPh 3 and P3-PPh 3 conjugates are promising candidates with ability to compromise tumor cells proliferation [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Triphenylphosphonium salts of 1,2,4-benzothiadiazine 1,1-dioxides related to diazoxide targeting mitochondrial ATP-sensitive potassium channels.
- Author
-
Constant-Urban, Céline, Charif, Mounia, Goffin, Eric, Van Heugen, Jean-Claude, Elmoualij, Benaïssa, Chiap, Patrice, Mouithys-Mickalad, Ange, Serteyn, Didier, Lebrun, Philippe, Pirotte, Bernard, and De Tullio, Pascal
- Subjects
- *
PHOSPHONIUM compounds , *DIAZINES , *OXIDES , *TARGETED drug delivery , *MITOCHONDRIAL pathology , *ADENOSINE triphosphate - Abstract
Abstract: The present work aims at identifying new ion channel modulators able to target mitochondrial ATP-sensitive potassium channels (mitoKATP channels). An innovative approach should consist in fixing a cationic and hydrophobic triphenylphosphonium fragment on the structure of known KATP channel openers. Such phosphonium salts are expected to cross the biological membranes and to accumulate into mitochondria. Previous works revealed that the presence of an (R)-1-hydroxy-2-propylamino chain at the 3-position of 4H-1,2,4-benzothiadiazine 1,1-dioxides KATP channel openers increased, in most cases, the selectivity towards the pancreatic-type (SUR1/Kir6.2) KATP channel. In order to target cardiac mitoKATP channels, we decided to introduce a triphenylphosphonium group through an ester link on the SUR1-selective (R)-7-chloro-3-(1-hydroxy-2-propyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide. The new compounds were found to preserve an inhibitory activity on insulin secretion (SUR1-type KATP channel openers) while no clear demonstration of an impact on mitochondria from cardiomyocytes (measurement of oxygen consumption, respiratory parameters and ATP production on H9C2 cells) was observed. However, the most active (inhibition of insulin release) compound 17 was found to penetrate the cardiac cells and to reach mitochondria. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
5. Liposomes and Liposome-like Vesicles for Drug and DNA Delivery to Mitochondria.
- Author
-
Weissig, Volkmar, Boddapati, Sarathi V., Cheng, Shing-Ming, and D'souza, Gerard G. M.
- Subjects
- *
LIPOSOMES , *DNA , *MITOCHONDRIA , *BILAYER lipid membranes , *CYTOPLASM - Abstract
Mitochondrial research is presently one of the fastest growing disciplines in biomedicine. Since the early 1990s, it has become increasingly evident that mitochondrial dysfunction contributes to a large variety of human disorders, ranging from neurodegenerative and neuromuscular diseases, obesity, and diabetes to ischemia-reperfusion injury and cancer. Most remarkably, mitochondria, the “power house” of the cell, have also become accepted as the “motor of cell death” reflecting their recognized key role during apoptosis. Based on these recent exciting developments in mitochondrial research, increasing pharmacological efforts have been made leading to the emergence of “Mitochondrial Medicine” as a whole new field of biomedical research. The identification of molecular mitochondrial drug targets in combination with the development of methods for selectively delivering biologically active molecules to the site of mitochondria will eventually launch a multitude of new therapies for the treatment of mitochondria-related diseases, which are based either on the selective protection, repair, or eradication of cells. Yet, while tremendous efforts are being undertaken to identify new mitochondrial drugs and drug targets, the development of mitochondria-specific drug carrier systems is lagging behind. To ensure a high efficiency of current and future mitochondrial therapeutics, colloidal vectors, i.e., delivery systems, need to be developed able to selectively transport biologically active molecules to and into mitochondria within living human cells. Here we review ongoing efforts in our laboratory directed toward the development of different phospholipid- and non-phospholipid-based mitochondriotropic drug carrier systems. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
6. Mitochondriotropic Liposomes.
- Author
-
Boddapati, Sarathi V., Tongcharoensirikul, Pakamas, Hanson, Robert N., D'Souza, Gerard G. M., Torchilin, Vladimir P., and Weissig, Volkmar
- Subjects
- *
LIPOSOMES , *CYTOPLASM , *MITOCHONDRIA , *MITOCHONDRIAL pathology , *CYTOLOGY , *PHARMACEUTICAL research , *MEDICAL research - Abstract
Mitochondrial dysfunction contributes to a large variety of human disorders, ranging from neurodegenerative and neuromuscular diseases, obesity, and diabetes to ischemia-reperfusion injury and cancer. Increasing pharmacological efforts toward therapeutic interventions have been made leading to the emergence of “Mitochondrial Medicine” as a new field of biomedical research. The identification of molecular mitochondrial drug targets in combination with the development of methods for selectively delivering biologically active molecules to the site of mitochondria will eventually launch a multitude of new therapies for the treatment of mitochondria-related diseases, which are based either on the selective protection, repair, or eradication of cells. Yet, while tremendous efforts are being undertaken to identify new mitochondrial drugs and drug targets, the development of mitochondria-specific drug carrier systems is lagging behind. To ensure a high efficiency of current and future mitochondrial therapeutics, delivery systems need to be developed, which are able to selectively transport biologically active molecules to and into mitochondria within living human cells. In this study we present the first data demonstrating that conventional liposomes can be rendered mitochondria-specific via the attachment of known mitochondriotropic residues to the liposomal surface. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.